Navigation Links
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Date:5/20/2008

HAYWARD, Calif., May 20 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced the appointment of Pamela S. Cohen, M.D., as Senior Vice President and Chief Medical Officer. Dr. Cohen is a recognized expert in the global development and registration of cancer therapeutics and has had a long and distinguished career as a medical oncologist and clinical pharmacologist, most notably at Novartis. Dr. Cohen joins Kosan from GE Healthcare Medical Diagnostics where she served as the Global Oncology Therapeutic Area Head, responsible for strategic development, clinical trial implementation and registration of the GE Healthcare-Medical Diagnostics Division's product portfolio of molecularly targeted imaging diagnostics.

"Pam's extensive experience in leading all aspects of cancer drug development and registration in worldwide markets and her work with a broad range of compound classes and tumor types will be of significant value to Kosan as we advance our Hsp90 inhibitor and epothilone programs through later stages of development," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Recruiting an experienced and accomplished chief medical officer was one of Kosan's major goals for 2008. We are delighted that Pam will be able to leverage her direct knowledge of cytotoxic and targeted oncology drug development to bring leadership, direction and focus to the execution of Kosan's development activities. Pam is well-known and respected throughout the oncology community as well as the pharmaceutical industry, and she will be instrumental in strengthening our partnering initiatives. Kosan's Board of Directors and management team join me in welcoming Pam to Kosan."

Dr. Cohen has been involved in
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
2. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
3. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
6. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
7. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
8. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
9. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
10. Kosan Announces February 28, 2008 Conference Call and Webcast
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
(Date:7/10/2014)... the fractional quantum Hall effect in bilayer graphene and ... tuned by an electric field. , The fractional ... to thin sheets are exposed to large magnetic fields, ... of individual electrons behave as a single system. However, ... established, many details of this collective behavior remain not ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... therapies for solid tumors and,hematological malignancies, today announced ... Officer is scheduled to present at the Thomas,Weisel ... the Four,Seasons Hotel in Boston. SuperGen,s presentation ...
... Aug. 29 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Thomas Weisel Partners Healthcare Conference 2007 will be ... Kevin Hrusovsky, President and CEO,of Caliper, will be ... http://www.veracast.com/webcasts/twp/healthcare07/98209449.cfm . An archived,presentation will be available for ...
... Aug. 28 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS, Nasdaq: PXSL) ... of,Bronchitol for the treatment of people with bronchiectasis ... life and mucus clearance. Data from the ... quality of life after 12 weeks of treatment ...
Cached Biology Technology:Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... -- Research and Markets has announced the ... Industry Analysis Size Share Growth Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number ... for high level security in both private and public ... username and passwords, tokens etc. are vulnerable to attacks. ...
(Date:7/10/2014)... Albuquerque, and other major cities in New Mexico, nearly ... municipal wastewater rather than precious potable water supplies. Across ... of all golf courses receive treated effluent. Reusing the ... Additionally, golf courses and homeowners alike fertilize their lawns ... is nitrate. A New Mexico State University turfgrass expert ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2'Tailored' water -- the latest in lawn care 2
... is available in French . Montreal -- ... consumers, thanks to Concordia University researchers who,ve developed a new ... products. "Even though Canada does not allow the use ... there were no methods or equipment to effectively measure residual ...
... With concerns about jobs in the headlines around the world, ... ( C&EN ) presents a 3-part cover story on the ... than 96% of all manufactured goods, with the chemical industry ... C&EN is the weekly newsmagazine of the American Chemical ...
... and BGI, the world,s largest genomics institute, today ... conduct large-scale human genome sequencing and bioinformatics analysis ... at Children,s Hospital. The partnership will focus on ... pediatric diseases using next-generation sequencing. The Center became ...
Cached Biology News:Children's Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center 2
Yersinia pestis...
... WinList come straight from the folks who ... automatic region positioning, N-Stat regions, and presentation-quality ... thoughtful conversations, and careful design. Of course, ... are still there, too. WinList leads the ...
Insect Cell Lysis Buffer 50 ml...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Biology Products: